An investigation on behalf of investors in Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares over potential wrongdoing at Orexigen Therapeutics, Inc. was announced and NASDAQ:OREX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 04/21/2017 -- An investigation was announced for investors in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) over potential breaches of fiduciary duties by certain directors at Orexigen Therapeutics, Inc.
Investors who purchased shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Orexigen Therapeutics directors breached their fiduciary duties.
Orexigen Therapeutics, Inc. reported that its annual Total Revenue rose from $24.46 million in 2105 to $33.71 million in 2016 and that its Net Loss declined from $68.69 million in 2015 to $24.52 million in 2016.
Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) closed on April 20, 2017 at $2.83 per share.
Those who purchased shares of Orexigen Therapeutics, Inc. have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com